Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of California, San Francisco, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, Seoul National University Hospital, Mayo Clinic in Arizona, National University Hospital, Duke Medical Center, Asan Medical Center, University of Ulsan, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Clinica Universidad de Navarra
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: durvalumab, tremelimumab, hepatocellular carcinoma, unresectable liver cancer, PD-L1 blockade, CTLA-4 blockade, immune checkpoint inhibitors, combination immunotherapy, treatment-related adverse events, hepatitis B, HCV infection, anticancer activity, pneumonitis, liver function tests, treatment efficacy and safety, Child-Pugh score
Open Access status: closed
OpenAlex ID: W2759382352
